Therefore, this study aimed to assess the potential of exosomal ANGPTL2 in cerebrospinal fluid (CSF) as a prognostic biomarker for PCNSL.<h4>Methods</h4>We retrospectively reviewed the medical records of patients newly diagnosed with PCNSL at our institution from May 2020 to September 2023. This evidence concerns the gene ANGPTL2 and primary central nervous system lymphoma.